Shanghai Henlius Biotech has attracted renewed investor attention after expanding its licensing agreement with Abbott, potentially unlocking new markets for one of its key products.
The revised deal grants Abbott rights to distribute the therapy across 42 additional countries and includes up to $126 million in potential milestone payments tied to development and commercialization progress.

Strong Share Price Momentum

The updated licensing agreement arrives amid a period of notable share price performance for the Hong Kong-listed biotech firm.
Henlius shares have gained roughly 10% over the past month and about 10.5% year to date. Over a longer timeframe, performance has been even stronger, with total shareholder returns of approximately 106% over the past year and significant gains over the last three years.
Such momentum has led investors to revisit the company’s valuation following the strategic update.

P/E Ratio Suggests Mixed Valuation Signals

Henlius currently trades at a price-to-earnings ratio of around 37.6x, a valuation that presents a mixed picture when compared with peers and sector averages.

Relative to comparable biotech companies, which trade at an average P/E near 47.9x, Henlius appears somewhat discounted. However, when measured against an estimated fair P/E of about 20.3x, the stock appears more expensive than valuation models might justify.
The company’s P/E also sits roughly in line with the broader Asian biotechnology sector average of about 37.3x.

This creates uncertainty for investors trying to determine whether the current valuation reflects genuine growth potential or already prices in much of the company’s expected progress.

Earnings Growth and Pipeline Potential

Henlius has recently transitioned into profitability, making valuation metrics particularly sensitive to future earnings expectations.
Over the past year, earnings have grown by about 19%, and growth over the past five years has been even stronger. Analysts still expect earnings to continue expanding, although the pace may moderate compared with the broader Hong Kong market.

Investors are also watching the company’s expanding biologics pipeline, which could provide additional growth opportunities but also carries regulatory and development risks.

DCF Model Suggests Possible Undervaluation

While the P/E ratio signals caution, a discounted cash flow (DCF) analysis paints a different picture.
Based on this method, Henlius’ share price of roughly HK$64.75 appears to trade significantly below an estimated intrinsic value of about HK$182.57. That would imply the stock is trading at a discount of more than 60%.
This divergence between valuation models highlights the challenge investors face when assessing high-growth biotech companies.

Investors Weigh Growth vs. Risk

Ultimately, investors must balance strong historical growth, expanding licensing partnerships, and a promising biologics pipeline against the risks inherent in pharmaceutical development.

Future regulatory approvals, commercial milestones, and sustained revenue growth will likely determine whether Henlius’ current valuation proves justified.